Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 41Observational 5Expanded_access 2

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 5Hyperglycemia 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 60palbociclib 37Trastuzumab 31Letrozole 26Immunohistochemistry 26Drug Therapy 24Anastrozole 24Radiotherapy 21Gene Expression Profiling 20Amplified Fragment Length Polymorphism Analysis 20Mastectomy, Segmental 19Biopsy 19Tamoxifen 18exemestane 17Interviews as Topic 17ribociclib 16Mastectomy 16Fulvestrant 16Paclitaxel 15Magnetic Resonance Spectroscopy 15Psychiatric Rehabilitation 14High-Energy Shock Waves 14Polymerase Chain Reaction 13Observation 13Microarray Analysis 13Capecitabine 13trastuzumab deruxtecan 12Neoadjuvant Therapy 12Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Observational × Breast Neoplasms × Alpelisib × Clear all
NCT06083038 2026-05-06

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

HealthPartners Institute

Completed
8 enrolled
Breast

Breast Neoplasms, Hyperglycemia

NCT05022342 2026-02-23

SPEAR

Novartis

Completed
595 enrolled
Breast

Breast Neoplasms

NCT04967248 2025-12-04

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Novartis

Terminated
4 enrolled
Breast

Breast Neoplasms

NCT05293470 2025-07-09

A Post Marketing Surveillance on Piqray in Korea

Novartis

Recruiting
900 enrolled
Breast

Breast Neoplasms

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Blokhin's Russian Cancer Research Center

Unknown
1,000 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡